TrinityPoint Wealth LLC Makes New Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

TrinityPoint Wealth LLC acquired a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 3,737 shares of the biopharmaceutical company’s stock, valued at approximately $214,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. GAMMA Investing LLC boosted its stake in Halozyme Therapeutics by 96.6% during the 2nd quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 254 shares during the last quarter. International Assets Investment Management LLC bought a new position in shares of Halozyme Therapeutics in the second quarter valued at approximately $33,000. Skandinaviska Enskilda Banken AB publ purchased a new position in shares of Halozyme Therapeutics during the second quarter valued at approximately $49,000. Toth Financial Advisory Corp bought a new stake in Halozyme Therapeutics during the third quarter worth $57,000. Finally, FSC Wealth Advisors LLC purchased a new stake in Halozyme Therapeutics in the 3rd quarter valued at $65,000. 97.79% of the stock is owned by institutional investors.

Halozyme Therapeutics Stock Performance

NASDAQ:HALO opened at $42.57 on Tuesday. The company has a market capitalization of $5.42 billion, a P/E ratio of 14.10, a P/E/G ratio of 0.42 and a beta of 1.29. The business has a fifty day simple moving average of $56.04 and a two-hundred day simple moving average of $53.48. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. Halozyme Therapeutics, Inc. has a 1 year low of $33.15 and a 1 year high of $65.53.

Insider Buying and Selling

In related news, CEO Helen Torley sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $59.20, for a total transaction of $592,000.00. Following the sale, the chief executive officer now directly owns 676,744 shares in the company, valued at approximately $40,063,244.80. This represents a 1.46 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In the last 90 days, insiders sold 70,000 shares of company stock valued at $4,042,500. 2.40% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on HALO shares. Benchmark reaffirmed a “buy” rating and set a $60.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, August 8th. HC Wainwright boosted their price target on shares of Halozyme Therapeutics from $65.00 to $68.00 and gave the stock a “buy” rating in a report on Friday, November 1st. TD Cowen increased their price objective on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. JPMorgan Chase & Co. downgraded Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and boosted their target price for the stock from $52.00 to $57.00 in a research note on Thursday, September 19th. Finally, The Goldman Sachs Group increased their price target on Halozyme Therapeutics from $44.00 to $49.00 and gave the company a “neutral” rating in a research report on Monday, July 22nd. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $61.11.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.